Recent News

• 06.11.2026 - Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
• 06.01.2026 - Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
• 05.18.2026 - Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
• 05.18.2026 - Alpha Tau to Participate in May Investor Conferences
• 05.11.2026 - Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® REGAIN Trial, with 100% Local Disease Control, 67% Complete Response Rate, aand Favorable Safety Profile Observed
• 05.08.2026 - Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma

Recent Filings

• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 144 Report of proposed sale of securities
• 06.03.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.03.2026 - EX-99.1 EX-99.1
• 06.01.2026 - EX-99.1 EX-99.1
• 06.01.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.18.2026 - EX-99.1 EX-99.1
• 05.18.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.18.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.18.2026 - EX-99.1 EX-99.1